Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01021358 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
A Phase 1 study of Lymphoma and Chronic Lymphocytic Leukemia, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01021358 is a Phase 1 study of Lymphoma and Chronic Lymphocytic Leukemia that has completed, run by Abbott. The registered enrollment target is 12 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01021358, a Phase 1 study of Lymphoma and Chronic Lymphocytic Leukemia, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single dose, open-label, single or multiple center study to determine the interaction of ketoconazole with ABT-263 in approximately 12 subjects with cancer.
Conditions Studied
Interventions
- DRUG Ketoconazole
- DRUG ABT-263
Study Locations (1)
Texas
- Site Reference ID/Investigator# 25068 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01021358
The ClinicalTrials.gov registry entry for NCT01021358 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (98% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Ketoconazole is the first listed.
NCT01021358 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01021358 about?
NCT01021358 is a clinical study titled "A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).". This is a single dose, open-label, single or multiple center study to determine the interaction of ketoconazole with ABT-263 in approximately 12 subjects with cancer.
What is the current status of trial NCT01021358?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-01.
What conditions does trial NCT01021358 study?
This clinical trial studies the following conditions: Lymphoma, Chronic Lymphocytic Leukemia, Solid Tumors.
What interventions are being tested in trial NCT01021358?
The interventions under investigation include: Ketoconazole (DRUG), ABT-263 (DRUG).
Who is sponsoring clinical trial NCT01021358?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01021358 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.